Viking: 3 Key Takeaways for Long-Term Investors
Viking (VKTX) initiated phase 3 trials for its oral weight-loss drug VK2735, showing potential for less frequent dosing. The company raised $960M to support trials and commercial prep. Management highlights competitive advantages in dosing flexibility.







